Best cytogenetic response to dasatinib
. | No. patients (%) . | |||
---|---|---|---|---|
6-mo follow-up . | 8-mo follow-up . | |||
MBC-CML . | LBC-CML . | MBC-CML . | LBC-CML . | |
No. of patients | 74 | 42 | 74 | 42 |
Overall cytogenetic response | 31 (42) | 24 (57) | 32 (43) | 24 (57) |
MCyR | 22 (30) | 21 (50) | 23 (31) | 21 (50) |
CCyR | 20 (27) | 18 (43) | 20 (27) | 18 (43) |
PCyR | 2 (3) | 3 (7) | 3 (4) | 3 (7) |
Minor cytogenetic response | 2 (3) | 0 (0) | 2 (3) | 0 (0) |
Minimal cytogenetic response | 7 (9) | 3 (7) | 7 (9) | 3 (7) |
Not evaluable | 19 (26) | 14 (33) | 18 (24) | 14 (33) |
. | No. patients (%) . | |||
---|---|---|---|---|
6-mo follow-up . | 8-mo follow-up . | |||
MBC-CML . | LBC-CML . | MBC-CML . | LBC-CML . | |
No. of patients | 74 | 42 | 74 | 42 |
Overall cytogenetic response | 31 (42) | 24 (57) | 32 (43) | 24 (57) |
MCyR | 22 (30) | 21 (50) | 23 (31) | 21 (50) |
CCyR | 20 (27) | 18 (43) | 20 (27) | 18 (43) |
PCyR | 2 (3) | 3 (7) | 3 (4) | 3 (7) |
Minor cytogenetic response | 2 (3) | 0 (0) | 2 (3) | 0 (0) |
Minimal cytogenetic response | 7 (9) | 3 (7) | 7 (9) | 3 (7) |
Not evaluable | 19 (26) | 14 (33) | 18 (24) | 14 (33) |
Not evaluable indicates patients who discontinued therapy before the first cytogenetic assessment.